Market Place
Sourcing Support
All News #Library
Biotech
Pierre Announces Type A Meeting Agreed with Tabelecleucel BLA
12 Mar 2026 //
PR NEWSWIRE
Pierre Fabre Eyes AI for New Clinical Studies in Dermo-Cosmetics
11 Mar 2026 //
PR NEWSWIRE
Pierre Fabre Seeks FDA Type A Meeting For BLA of Tabelecleucel
03 Mar 2026 //
PR NEWSWIRE
Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
03 Mar 2026 //
BUSINESSWIRE
Pierre Fabre, Iktos Launch Integrated Drug Discovery in Oncology
09 Jan 2026 //
PR NEWSWIRE
Pierre Takes Over Tabelecleucel Drug Application from Atara Bio
15 Jul 2025 //
PR NEWSWIRE
Jubilant Biosys seals deal with Pierre Fabre SA
17 Feb 2025 //
EXPRESSPHARMA
Phase 3 Allele Study Confirms Tabelecleucel`s Efficacy In EBV+ PTLD
07 Dec 2024 //
PR NEWSWIRE
Pierre Fabre Doses First Patient In PFL-002 Phase I/II For NSCLC
24 Oct 2024 //
PR NEWSWIRE
Jubilant Biosys signs partnership with Pierre Fabre SA
10 Oct 2024 //
EXPRESSPHARMA
Pierre Fabre Laboratories Announce European Authorization For OBGEMSA
28 Jun 2024 //
PR NEWSWIRE
Pierre Fabre: IND For PFL-002/VERT-002 In Solid Tumors With MET Mutations
05 Jun 2024 //
PR NEWSWIRE
Pierre Fabre: Positive CHMP Opinion for OBGEMSA™ in OAB
26 Apr 2024 //
PR NEWSWIRE
Pierre Fabre and the EspeRare Foundation to be honored with the EURORDIS Award
15 Feb 2024 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.